<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://new.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Tue, 21 Jul 2026 16:05:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://new.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>First Advantage Named to TIME’s 2026 List of America’s Best Companies </title>
   <link>http://www.streetinsider.com/Press+Releases/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies+/26795533.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Recognition Showcases Commitment to Company Culture, Financial Performance, and Sustainability&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;ATLANTA, July  21, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, today announced it has been included on TIME’s list of America’s Best Companies 2026, ranking #1 in Background Screening and Identity Verification. This award is presented in collaboration with Statista, a world-leading statistics portal and industry ranking provider.&lt;/p&gt;  &lt;p&gt;TIME and Statista identified America’s Best Companies 2026 based on three primary dimensions:&lt;/p&gt;  &lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:5pt; margin-bottom:5pt;&quot;&gt;&lt;strong&gt;Employee Satisfaction&lt;/strong&gt; – Based on survey data from ~217,000 verified employees at U.S. companies over</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies+/26795533.html</guid>
   <pubDate>Tue, 21 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	  </item>
  <item>
   <title>First Advantage Named to TIME’s 2026 List of America’s Best Companies </title>
   <link>http://www.streetinsider.com/Press+Releases/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies+/26795533.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Recognition Showcases Commitment to Company Culture, Financial Performance, and Sustainability&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;ATLANTA, July  21, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, today announced it has been included on TIME’s list of America’s Best Companies 2026, ranking #1 in Background Screening and Identity Verification. This award is presented in collaboration with Statista, a world-leading statistics portal and industry ranking provider.&lt;/p&gt;  &lt;p&gt;TIME and Statista identified America’s Best Companies 2026 based on three primary dimensions:&lt;/p&gt;  &lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:5pt; margin-bottom:5pt;&quot;&gt;&lt;strong&gt;Employee Satisfaction&lt;/strong&gt; – Based on survey data from ~217,000 verified employees at U.S. companies over</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies+/26795533.html</guid>
   <pubDate>Tue, 21 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	  </item>
  <item>
   <title>First Advantage Named to TIME’s 2026 List of America’s Best Companies </title>
   <link>http://www.streetinsider.com/Globe+Newswire/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies+/26795533.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Recognition Showcases Commitment to Company Culture, Financial Performance, and Sustainability&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;ATLANTA, July  21, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, today announced it has been included on TIME’s list of America’s Best Companies 2026, ranking #1 in Background Screening and Identity Verification. This award is presented in collaboration with Statista, a world-leading statistics portal and industry ranking provider.&lt;/p&gt;  &lt;p&gt;TIME and Statista identified America’s Best Companies 2026 based on three primary dimensions:&lt;/p&gt;  &lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:5pt; margin-bottom:5pt;&quot;&gt;&lt;strong&gt;Employee Satisfaction&lt;/strong&gt; – Based on survey data from ~217,000 verified employees at U.S. companies over</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies+/26795533.html</guid>
   <pubDate>Tue, 21 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	  </item>
  <item>
   <title>First Advantage Named to TIME’s 2026 List of America’s Best Companies </title>
   <link>http://www.streetinsider.com/Globe+Newswire/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies+/26795533.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Recognition Showcases Commitment to Company Culture, Financial Performance, and Sustainability&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;ATLANTA, July  21, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, today announced it has been included on TIME’s list of America’s Best Companies 2026, ranking #1 in Background Screening and Identity Verification. This award is presented in collaboration with Statista, a world-leading statistics portal and industry ranking provider.&lt;/p&gt;  &lt;p&gt;TIME and Statista identified America’s Best Companies 2026 based on three primary dimensions:&lt;/p&gt;  &lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:5pt; margin-bottom:5pt;&quot;&gt;&lt;strong&gt;Employee Satisfaction&lt;/strong&gt; – Based on survey data from ~217,000 verified employees at U.S. companies over</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies+/26795533.html</guid>
   <pubDate>Tue, 21 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	  </item>
  <item>
   <title>First Advantage Named to TIME’s 2026 List of America’s Best Companies</title>
   <link>http://www.streetinsider.com/Press+Releases/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies/26795536.html</link>
   <description>
&lt;p&gt;ATLANTA, July  21, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, today announced it has been included on TIME’s list of America’s Best Companies 2026, ranking #1 in Background Screening and Identity Verification. This award is presented in collaboration with Statista, a world-leading statistics portal and industry ranking provider.&lt;/p&gt;  &lt;p&gt;TIME and Statista identified America’s Best Companies 2026 based on three primary dimensions:&lt;/p&gt;  &lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:5pt; margin-bottom:5pt;&quot;&gt;&lt;strong&gt;Employee Satisfaction&lt;/strong&gt; – Based on survey data from ~217,000 verified employees at U.S. companies over the past three years, covering company recommendations and employer</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies/26795536.html</guid>
   <pubDate>Tue, 21 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.50996177</category>
   	  </item>
  <item>
   <title>First Advantage Named to TIME’s 2026 List of America’s Best Companies</title>
   <link>http://www.streetinsider.com/Press+Releases/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies/26795536.html</link>
   <description>
&lt;p&gt;ATLANTA, July  21, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, today announced it has been included on TIME’s list of America’s Best Companies 2026, ranking #1 in Background Screening and Identity Verification. This award is presented in collaboration with Statista, a world-leading statistics portal and industry ranking provider.&lt;/p&gt;  &lt;p&gt;TIME and Statista identified America’s Best Companies 2026 based on three primary dimensions:&lt;/p&gt;  &lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:5pt; margin-bottom:5pt;&quot;&gt;&lt;strong&gt;Employee Satisfaction&lt;/strong&gt; – Based on survey data from ~217,000 verified employees at U.S. companies over the past three years, covering company recommendations and employer</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies/26795536.html</guid>
   <pubDate>Tue, 21 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.50996177</category>
   	  </item>
  <item>
   <title>First Advantage Named to TIME’s 2026 List of America’s Best Companies</title>
   <link>http://www.streetinsider.com/Globe+Newswire/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies/26795536.html</link>
   <description>
&lt;p&gt;ATLANTA, July  21, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, today announced it has been included on TIME’s list of America’s Best Companies 2026, ranking #1 in Background Screening and Identity Verification. This award is presented in collaboration with Statista, a world-leading statistics portal and industry ranking provider.&lt;/p&gt;  &lt;p&gt;TIME and Statista identified America’s Best Companies 2026 based on three primary dimensions:&lt;/p&gt;  &lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:5pt; margin-bottom:5pt;&quot;&gt;&lt;strong&gt;Employee Satisfaction&lt;/strong&gt; – Based on survey data from ~217,000 verified employees at U.S. companies over the past three years, covering company recommendations and employer</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies/26795536.html</guid>
   <pubDate>Tue, 21 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.50996177</category>
   	  </item>
  <item>
   <title>First Advantage Named to TIME’s 2026 List of America’s Best Companies</title>
   <link>http://www.streetinsider.com/Globe+Newswire/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies/26795536.html</link>
   <description>
&lt;p&gt;ATLANTA, July  21, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, today announced it has been included on TIME’s list of America’s Best Companies 2026, ranking #1 in Background Screening and Identity Verification. This award is presented in collaboration with Statista, a world-leading statistics portal and industry ranking provider.&lt;/p&gt;  &lt;p&gt;TIME and Statista identified America’s Best Companies 2026 based on three primary dimensions:&lt;/p&gt;  &lt;ul type=&quot;disc&quot;&gt;&lt;li style=&quot;margin-top:5pt; margin-bottom:5pt;&quot;&gt;&lt;strong&gt;Employee Satisfaction&lt;/strong&gt; – Based on survey data from ~217,000 verified employees at U.S. companies over the past three years, covering company recommendations and employer</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/First+Advantage+Named+to+TIME%E2%80%99s+2026+List+of+America%E2%80%99s+Best+Companies/26795536.html</guid>
   <pubDate>Tue, 21 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.50996177</category>
   	  </item>
  <item>
   <title>First Advantage to Release Second Quarter 2026 Financial Results and Hold Investor Conference Call on August 6, 2026</title>
   <link>http://www.streetinsider.com/Press+Releases/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html</link>
   <description>&lt;p&gt;ATLANTA, July  16, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, will issue its second quarter 2026 financial results on Thursday, August 6, 2026 prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Conference Call Details&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;To participate in the conference call, please dial 800-274-8461 (domestic) or 203-518-9814 (international) approximately ten minutes before the 8:30 a.m. ET start. Please mention to the operator that you are dialing in for the First Advantage second quarter 2026 earnings call or</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html</guid>
   <pubDate>Thu, 16 Jul 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	  </item>
  <item>
   <title>First Advantage to Release Second Quarter 2026 Financial Results and Hold Investor Conference Call on August 6, 2026</title>
   <link>http://www.streetinsider.com/Press+Releases/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html</link>
   <description>&lt;p&gt;ATLANTA, July  16, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, will issue its second quarter 2026 financial results on Thursday, August 6, 2026 prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Conference Call Details&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;To participate in the conference call, please dial 800-274-8461 (domestic) or 203-518-9814 (international) approximately ten minutes before the 8:30 a.m. ET start. Please mention to the operator that you are dialing in for the First Advantage second quarter 2026 earnings call or</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html</guid>
   <pubDate>Thu, 16 Jul 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	  </item>
  <item>
   <title>First Advantage to Release Second Quarter 2026 Financial Results and Hold Investor Conference Call on August 6, 2026</title>
   <link>http://www.streetinsider.com/Globe+Newswire/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html</link>
   <description>&lt;p&gt;ATLANTA, July  16, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, will issue its second quarter 2026 financial results on Thursday, August 6, 2026 prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Conference Call Details&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;To participate in the conference call, please dial 800-274-8461 (domestic) or 203-518-9814 (international) approximately ten minutes before the 8:30 a.m. ET start. Please mention to the operator that you are dialing in for the First Advantage second quarter 2026 earnings call or</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html</guid>
   <pubDate>Thu, 16 Jul 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	  </item>
  <item>
   <title>First Advantage to Release Second Quarter 2026 Financial Results and Hold Investor Conference Call on August 6, 2026</title>
   <link>http://www.streetinsider.com/Globe+Newswire/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html</link>
   <description>&lt;p&gt;ATLANTA, July  16, 2026  (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, will issue its second quarter 2026 financial results on Thursday, August 6, 2026 prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;Conference Call Details&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;To participate in the conference call, please dial 800-274-8461 (domestic) or 203-518-9814 (international) approximately ten minutes before the 8:30 a.m. ET start. Please mention to the operator that you are dialing in for the First Advantage second quarter 2026 earnings call or</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html</guid>
   <pubDate>Thu, 16 Jul 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
 </channel>
</rss>
